Company / Return on Assets (ROA)
Cogent Biosciences, Inc. Return on Assets (ROA) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-35.1%
FY2025
5-year range
-78.0% / -31.1%
FY2021-FY2025
Trend
+55.0%
vs FY2024
Sector context
#147 of 213
Health Care
What the data says
At -35.1%, Cogent Biosciences, Inc.'s return on assets (roa) ranks #147 of 213 in the Health Care sector. Return on Assets (ROA) returned to growth in FY2025 after 4 years of decline, reaching -35.1%.
Based on SEC 10-K filings.
-35.1% in FY2025 with a 5-year CAGR of -5.3%.
Improved from -61.4% to -35.1% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +11.5pp
- 5-Year Change
- -5.3pp
- 10-Year Change
- -
Sector benchmark
#147 of 213 in Health CareTop 69% of 213This company -35.1% Sector average -24.1%
▼
-45.3% below sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) increased 55.0% year-over-year.
- Currently 10.9pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2020.
- Lowest return on assets (roa) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -35.1% | +55.0% |
| FY2024 | -78.0% | -27.1% |
| FY2023 | -61.4% | -31.7% |
| FY2022 | -46.6% | -49.7% |
| FY2021 | -31.1% | -4.5% |
| FY2020 | -29.8% | +53.7% |
| FY2019 | -64.4% | -60.3% |
| FY2018 | -40.2% | +22.6% |
| FY2017 | -51.9% | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026